|Description:||Renin, a highly specific aspartyl protease, cleaves angiotensinogen, to yield angiotensin I, which is further converted into angiotensin II by ACE (Angiotensin ConvertingEnzyme). Angiotensin II constricts blood vessels leading to increased blood pressure. It also increases the secretion of ADH and aldosterone, and stimulates the hypothalamus to activate the thirst reflex. Since an overactive renin-angiotensin system leads to hypertension, renin is an attractive target for the treatment of this disease. The SensoLyte® 390 Renin Assay Kit provides a convenient assay for high throughput screening of renin inhibitors and for continuous assay of renin activity using a Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide. In the FRET peptide the fluorescence of Mc-Ala is quenched by Dnp. Upon cleavage into two separate fragments by renin, the fluorescence of Mc-Ala is recovered, and can be monitored at excitation/emission = 330/390 nm. This assay is about four fold more sensitive than an EDANS/DABCYL-based assay and can detect 8 ng/ml of renin. The kit contains:, Mc-Ala/Dnp-based FRET peptide substrate (Ex/Em=330/390 nm upon cleavage), Assay buffer, Human recombinant renin, Renin inhibitor, Fluorescence reference standard for calibration, A detailed protocol|
|Unit Size:||1 kit|
|Restrictions:||Only available in Germany and selected European countries.|
|Storage:||Component C at -80 °C, all other components at -20 °C|
|More information:||Go to webpage|
*All prices are net in Euro and do not include applicable taxes, shipping & handling, or other charges (e.g., customs duties).
Delivery time approx. 8 - 10 days
- Phone: +49 (0)551 707 22 70
- E-mail: firstname.lastname@example.org
How To Order
Orders can be placed by phone, fax, e-mail, or via our online shop:
After placing your order, you will receive an order confirmation via e-mail within 2 working days. If you do not receive this e-mail, please contact us by phone. Thank you! More information regarding our ordering process can be found here.